{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:50:48Z","timestamp":1791978648469,"version":"4.4.0"},"reference-count":34,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Johnson & Johnson Innovative Medicine"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"DOI":"10.1080\/14737167.2026.2739076","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:15:02Z","timestamp":1790766902000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed\/refractory multiple myeloma: a multi-criteria decision analysis study"],"prefix":"10.1080","author":[{"given":"Mar\u00eda Victoria","family":"Mateos Manteca","sequence":"first","affiliation":[{"name":"University Hospital of Salamanca, CIBERONC and Institute of Biomedical Research of Salamanca (IBSAL)","place":["Salamanca, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Poveda Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Hospital Universitari i Polit\u00e8cnic La Fe","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol Rocafiguera","sequence":"additional","affiliation":[{"name":"Hospital Germans Trias i Pujol","place":["Badalona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n. Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Trillo Mata","sequence":"additional","affiliation":[{"name":"University Clinical Hospital of Valencia","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"G\u00f3mez Pajuelo","sequence":"additional","affiliation":[{"name":"The Spanish Ministry of Health","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Arribas Ruiz","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Dom\u00ednguez Lubillo","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Vidal-Vilar","sequence":"additional","affiliation":[{"name":"Outcomes\u201910 (A ProductLife Group Company)","place":["Castell\u00f3n de la Plana, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"As\u00eds","family":"Ariznavarreta Mart\u00edn","sequence":"additional","affiliation":[{"name":"Outcomes\u201910 (A ProductLife Group Company)","place":["Castell\u00f3n de la Plana, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.01.016"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"issue":"4","key":"e_1_3_5_7_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.clml.2023.12.001","article-title":"Characterization and outcomes of Spanish patients with relapsed\/refractory multiple myeloma included in the LocoMMotion study","volume":"24","author":"Mateos MV","year":"2024","unstructured":"Mateos MV, Weisel K, Diels J, et al. Characterization and outcomes of Spanish patients with relapsed\/refractory multiple myeloma included in the LocoMMotion study. Clin Lymphoma Myeloma Leuk. 2024;24(4):224\u2013231.e2.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01479-5"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092"},{"key":"e_1_3_5_10_1","unstructured":"European Medicines Agency. Carvykti: EPAR medicine overview. 2024 [cited 2025 May 1]. Available from: https:\/\/www.ema.europa.eu\/es\/documents\/overview\/carvykti-epar-medicine-overview_es.pdf"},{"key":"e_1_3_5_11_1","unstructured":"Ministerio de Sanidad. Acuerdos de la Comisi\u00f3n Interministerial de Precios de los Medicamentos: sesi\u00f3n 255. 2025 [cited 2025 May 1]. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/ACUERDOS_CIPM_255.pdf"},{"key":"e_1_3_5_12_1","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de Carvykti ciltacabtag\u00e9n autoleucel IPT-339. 2025 [cited 2025 May 1]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/2025\/IPT-339-Carvykti-ciltacabtagen-autoleucel.pdf"},{"issue":"17","key":"e_1_3_5_13_1","doi-asserted-by":"crossref","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care, PVd or DPd, in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal B","year":"2023","unstructured":"Dhakal B, Yong K, Harrison SJ, et al. First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care, PVd or DPd, in lenalidomide-refractory multiple myeloma. J Clin Oncol. 2023;41(17 suppl):LBA106.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_14_1","volume-title":"Presented at: 21st International Myeloma Society Annual Meeting","author":"Mateos MV","year":"2024","unstructured":"Mateos MV, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update [conference presentation]. Presented at: 21st International Myeloma Society Annual Meeting; Brazil. Rio de Janeiro; 2024 Sep 25\u201328."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.12.008"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-1007-x"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.18609\/cgti.2020.111"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07486-5"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.12.011"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.18609\/cgti.2021.104"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.12.003"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-8-270"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-016-0257-x"},{"issue":"3","key":"e_1_3_5_24_1","first-page":"126","article-title":"The nominal group technique: a useful consensus methodology in physiotherapy research","volume":"32","author":"Potter M","year":"2004","unstructured":"Potter M, Gordon S, Hamer P. The nominal group technique: a useful consensus methodology in physiotherapy research. NZ J Physiother. 2004;32(3):126\u2013130.","journal-title":"NZ J Physiother"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.2007.04227.x"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00487"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3258-9"},{"issue":"1","key":"e_1_3_5_28_1","doi-asserted-by":"crossref","first-page":"1511679","DOI":"10.1080\/20016689.2018.1511679","article-title":"Establishing the cost of implementing a performance-based managed entry agreement for a hypothetical CAR T-cell therapy","volume":"6","author":"Kefalas P","year":"2018","unstructured":"Kefalas P, Ali O, Jorgensen J, et al. Establishing the cost of implementing a performance-based managed entry agreement for a hypothetical CAR T-cell therapy. J Mark Access Health Policy. 2018;6(1):1511679.","journal-title":"J Mark Access Health Policy"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1715536"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0169"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2015.12.016"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-7547-8-4"},{"issue":"9","key":"e_1_3_5_33_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos MA","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91.","journal-title":"Blood Cancer J"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235886"},{"key":"e_1_3_5_35_1","unstructured":"Ministerio de Sanidad. Protocolo farmacocl\u00ednico del uso de tisagenlecleucel y axicabtag\u00e9n ciloleucel en el linfoma B difuso de c\u00e9lulas grandes en el Sistema Nacional de Salud. 2025 [cited 2025 May 1]. Available from: https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoMedicamentos\/valtermed\/docs\/11042025_Protocolo_farmacoclinico_tisagenlecleucel_axicel_LBDCG.pdf"},{"issue":"3","key":"e_1_3_5_36_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson LD","year":"2022","unstructured":"Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 2022;18(3):277\u2013289.","journal-title":"Future Oncol"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2739076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2026.2739076","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2739076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:01Z","timestamp":1791976081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2739076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":34,"alternative-id":["10.1080\/14737167.2026.2739076"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2739076","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}